Analyst at Cantor Fitzgerald explained that it's because new dosage will require additional trials, ultimately this will delay commercialization and potentially diminish the company’s advantage over competitor Ascendis.
A copy of the original text: "Although we believe these pivotal data are insufficient to support approval, we believe that optimizing for a higher dose administered more frequently could achieve the range of activity to demonstrate non-inferiority,” analyst Elemer Piros wrote in a note.